Figure 7.
Anti-hypertensive effects of AVE3085 in SHR. In (A) oral administration of AVE3085 for 4 weeks reduced systolic blood pressure in SHR but had no effects on systolic blood pressure in WKY rats. In panel (B), male eNOS−/− mice (4 months old) had a significantly higher systolic blood pressure than the wild-type C57BL/6J mice, but treatment of eNOS−/− mice with AVE3085 for up to 8 weeks had no effect on blood pressure. Data are mean ± SEM of five to seven animals. WT: wild-type mice, AVE(+): with AVE3085 treatment, AVE(–): without AVE3085 treatment. ##P < 0.001 versus WKY control, **P < 0.001 versus control, *P < 0.05 versus WT.